In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide
about
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive InfectionsProbiotic-based strategies for therapeutic and prophylactic use against multiple gastrointestinal diseasesIn vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.Vancomycin-resistant enterococci.Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionExperimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitisQuantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophagesModerate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci.Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
P2860
Q26772897-D314991F-0E17-41FF-9837-1ED7A66F8F77Q26800020-1F26E985-B3D3-4CF2-AA44-8A5DF8069241Q33697465-C057EFC2-FC34-4475-B493-28FDC8FC87D3Q33698979-5BA2A537-9A65-44FD-B8B8-B8D1F7DBD5FEQ33975592-8C85CB32-1E7D-4337-BCD8-84B533F3DA59Q33975885-038E5EBE-5445-46F3-8414-D6811C63CA6CQ33979559-BA1A7A45-1C59-473C-8267-EF4C5E91CEE4Q34937444-D45F080E-562A-48E1-A4D8-C1CD012C098BQ35013994-1D855E0D-48F0-4FB1-BB6B-CC5E42A3621DQ35102754-65DD5CF1-6887-4AE1-8EB0-8F097C7BAE2CQ39471427-E42478B9-8C08-41C7-A6AD-13B0B1CED0B7Q40165422-AA1EAEEA-C20A-4E05-8AB4-D7E30D381FFEQ50053159-1C602C61-E963-4044-A004-5B3E5EA98D71
P2860
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide
description
1997 nî lūn-bûn
@nan
1997 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide
@ast
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide
@en
type
label
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide
@ast
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide
@en
prefLabel
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide
@ast
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide
@en
P2093
P2860
P356
P1476
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide
@en
P2093
P2860
P304
P356
10.1128/AAC.41.10.2165
P407
P577
1997-10-01T00:00:00Z